MedTrace Logo

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

NCT05561816 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2023-10-10

No results posted yet for this study

Summary

The study is aimed to:

* evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma,
* evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.

Conditions

  • Pyoderma

Interventions

DRUG

Hydroxymethylquinoxalindioxyde

Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).

DRUG

Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium

Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-19
Primary Completion
2022-11-28
Completion
2022-12-20

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05561816 on ClinicalTrials.gov